The estimated Net Worth of Michael Celano is at least $1.47 Milion dollars as of 12 August 2022. Mr. Celano owns over 12,000 units of Orasure Technologies stock worth over $475,248 and over the last 18 years he sold OSUR stock worth over $772,782. In addition, he makes $219,998 as Independent Chairman of the Board at Orasure Technologies.
Michael has made over 5 trades of the Orasure Technologies stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 12,000 units of OSUR stock worth $53,880 on 12 August 2022.
The largest trade he's ever made was selling 44,962 units of Orasure Technologies stock on 5 May 2017 worth over $672,182. On average, Michael trades about 2,552 units every 53 days since 2006. As of 12 August 2022 he still owns at least 111,823 units of Orasure Technologies stock.
You can see the complete history of Mr. Celano stock trades at the bottom of the page.
Michael Celano serves as Independent Chairman of the Board of the Company. Mr. Celano has served as the Chief Operating Officer of Recro Pharma, Inc. and between July 2016 and January 2018, Mr. Celano served as Chief Financial Officer at Recro Pharma. Between 2015 and June 2016 Mr. Celano was self-employed providing consulting services to healthcare companies. From 2013 to 2015, Mr. Celano served as Chief Financial Officer of DrugScan, Inc. a clinical laboratory services company. Prior to that, Mr. Celano served as the Chief Financial Officer of Kensey Nash Corporation, a biomaterials company from 2009 to 2012. From 2007 to 2008, Mr. Celano also served as Chief Financial Officer for BioRexis Pharmaceutical Corporation, a biopharmaceutical company. Before joining BioRexis, Mr. Celano served as a partner with KPMG LLP, where he was co-leader of its National Life Science Practice. Mr. Celano also was co-leader of the Life Science Practice for Arthur Andersen before he joined KPMG. Mr. Celano also served on the Board of Directors of Performance Health, a consumer health care product manufacturing company from 2015 to 2016. Mr. Celano holds a B.S. in Accounting from St. Joseph’s University.
As the Independent Chairman of the Board of Orasure Technologies, the total compensation of Michael Celano at Orasure Technologies is $219,998. There are 7 executives at Orasure Technologies getting paid more, with Stephen Tang having the highest compensation of $2,114,820.
Michael Celano is 61, he's been the Independent Chairman of the Board of Orasure Technologies since 2018. There are 1 older and 15 younger executives at Orasure Technologies. The oldest executive at Orasure Technologies Inc. is Ronny Lancaster, 68, who is the Independent Director.
Michael's mailing address filed with the SEC is 220 EAST FIRST STREET, , BETHLEHEM, PA, 18015.
Over the last 21 years, insiders at Orasure Technologies have traded over $21,897,384 worth of Orasure Technologies stock and bought 196,200 units worth $1,037,188 . The most active insiders traders include Douglas A Michels, Ronald H Spair a Michael J Gausling. On average, Orasure Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $221,123. The most recent stock trade was executed by Kathleen Gallagher Weber on 19 December 2023, trading 24,129 units of OSUR stock currently worth $194,238.
based in bethlehem, pennsylvania, orasure technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. these products include tests for the detection of antibodies to the hiv virus, including the oraquick® in-home hiv test, oraquick advance® rapid hiv-1/2 antibody test and the orasure® hiv-1 oral specimen collection device, a test for antibodies to the hcv virus, the oraquick® hcv rapid antibody test, and oral fluid testing solutions for drugs of abuse testing, including intercept® oral fluid drug testing system and q.e.d.® saliva alcohol test. orasure also manufactures and sells several leading cryosurgical products. these include: histofreezer®, a product for the cryosurgical removal of common and plantar warts and several other benign skin lesions, sold to the professional or physician office market, as well as an over-the-counter product fo
Orasure Technologies executives and other stock owners filed with the SEC include: